Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1696704 | 1.00 | ALOX5 (0.43) | ALOX5SLC1A3SLC1A2SLC1A1MAOB | |
| SCHEMBL29175498 | 0.77 | — | — | |
| SCHEMBL1915949 | 0.76 | MAOB (0.38) | ALOX5MAOBALDH1A1CYP3A4ALOX15 | |
| SCHEMBL2022682 | 0.74 | — | — | |
| SCHEMBL9755560 | 0.74 | — | — | |
| SCHEMBL14478276 | 0.74 | — | — | |
| SCHEMBL4657408 | 0.74 | — | — | |
| SCHEMBL13692285 | 0.74 | — | — | |
| SCHEMBL10664022 | 0.73 | SLC1A3 (0.44) | ALOX5SLC1A3SLC1A2SLC1A1MAOB | |
| SCHEMBL1696705 | 0.73 | SLC1A3 (0.44) | ALOX5SLC1A3SLC1A2SLC1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585482-B1 | GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2019-03-27 | — | — | EP | claimed |
| US-20150376257-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2015-12-31 | — | — | US | claimed |
| US-20130157929-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | claimed |
| EP-2585482-A1 | GLUCAGON ANALOGUES | Zealand Pharma A/S (DK) | 2013-05-01 | — | — | EP | claimed |
| WO-2011160633-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2011-12-29 | — | — | WO | claimed |
| US-7335516-B2 | Methods to improve immunogenicity of antigens and specificity of antibodies | SEREX, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| EP-1451210-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1421107-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030125259-A1 | Octa- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-07-03 | — | — | US | claimed |
| US-20030109455-A1 | HEPTA-, OCTA-and nonapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | claimed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | claimed |
| WO-2003037268-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | claimed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | claimed |
| WO-2003011896-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-02-13 | — | — | WO | claimed |
| EP-2585482-B1 | GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2019-03-27 | — | — | EP | disclosed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | disclosed |
| WO-2003011896-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376257-A1 | GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | ALOX5 4000/4885SLC1A3 2769/4885SLC1A2 4014/4885 |
| US-20130157929-A1 | GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | ALOX5 4000/4885SLC1A3 2769/4885SLC1A2 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.